January 22, 2026 16:05 ET | Source: Adaptive Biotechnologies SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:…
PERFORMANCE FOR THE QUARTER ENDED DECEMBER 31, 2025Individual weighted premium income of ₹ 1,915.3 crore with a year-on-year growth of…
Results demonstrate a favorable safety profile and functional improvements in patients with severe tricuspid regurgitation including patients with reduced right…
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in premier…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT…
CHARLOTTE, N.C., Jan. 14, 2026 /PRNewswire/ -- Bank of America reported its fourth quarter 2025 financial results today. The news…
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…
January 11, 2026 09:30 ET | Source: RxSight, Inc. ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…